These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 16457254)
1. [IMRD therapy for patients with metastatic pancreas cancer]. Yamashita K; Takahashi Y Nihon Rinsho; 2006 Jan; 64 Suppl 1():219-22. PubMed ID: 16457254 [No Abstract] [Full Text] [Related]
2. A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer. Takahashi Y; Mai M; Sawabu N; Nishioka K Pancreas; 2005 Apr; 30(3):206-10. PubMed ID: 15782095 [TBL] [Abstract][Full Text] [Related]
3. [Tailored-dose chemotherapy using gemcitabine for advanced pancreatic cancer]. Sumii T; Fujimori N; Nakamura T; Senju T; Horikawa Y; Funakoshi A Gan To Kagaku Ryoho; 2006 Sep; 33(9):1261-5. PubMed ID: 16969022 [TBL] [Abstract][Full Text] [Related]
4. Putting the chemo in chemoradiation for pancreatic cancer. Lowy AM Ann Surg Oncol; 2006 Feb; 13(2):135-6. PubMed ID: 16411142 [No Abstract] [Full Text] [Related]
5. Gemcitabine doublets in advanced pancreatic cancer: should we move on? Rocha Lima CM; Flores AM J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312 [No Abstract] [Full Text] [Related]
6. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial. Girard N; Mornex F; Bossard N; Ychou M; Chauffert B; Wautot V Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1426-32. PubMed ID: 20056351 [TBL] [Abstract][Full Text] [Related]
7. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Joensuu TK; Kiviluoto T; Kärkkäinen P; Vento P; Kivisaari L; Tenhunen M; Westberg R; Elomaa I Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):444-52. PubMed ID: 15380578 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer. Robertson JM; Margolis J; Jury RP; Balaraman S; Cotant MB; Ballouz S; Boxwala IG; Jaiyesimi IA; Nadeau L; Hardy-Carlson M; Marvin KS; Wallace M; Ye H Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e187-92. PubMed ID: 21549514 [TBL] [Abstract][Full Text] [Related]
9. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Crane CH; Antolak JA; Rosen II; Forster KM; Evans DB; Janjan NA; Charnsangavej C; Pisters PW; Lenzi R; Papagikos MA; Wolff RA Int J Gastrointest Cancer; 2001; 30(3):123-32. PubMed ID: 12540024 [TBL] [Abstract][Full Text] [Related]
10. [Pancreatic carcinoma: progress in therapy]. Lordick F Krankenpfl J; 2004; 42(5-6):158-9. PubMed ID: 15527223 [No Abstract] [Full Text] [Related]
11. Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma. Meyer F; Lueck A; Hribaschek A; Lippert H; Ridwelski K Chemotherapy; 2004 Dec; 50(6):289-96. PubMed ID: 15608445 [TBL] [Abstract][Full Text] [Related]
12. Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study. Beane JD; Griffin KF; Levy EB; Pandalai P; Wood B; Abi-Jaoudeh N; Beresnev T; Shutack Y; Webb CC; Avital I; Rudloff U Invest New Drugs; 2015 Feb; 33(1):109-18. PubMed ID: 25236592 [TBL] [Abstract][Full Text] [Related]
14. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Ikeda M; Okada S; Tokuuye K; Ueno H; Okusaka T Br J Cancer; 2002 May; 86(10):1551-4. PubMed ID: 12085203 [TBL] [Abstract][Full Text] [Related]
15. Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. Eckel F; Schmelz R; Erdmann J; Mayr M; Lersch C Cancer Invest; 2003; 21(5):690-4. PubMed ID: 14628426 [TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of randomized trials: evaluation of benefit of gemcitabine-based molecular targeted therapy for inoperable pancreatic cancer. Cao Y; Wu L; Tan A; Liu L; Liao C; Gao F Pancreas; 2010 Mar; 39(2):253-5. PubMed ID: 20182311 [No Abstract] [Full Text] [Related]
17. Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer. Yamauchi J; Kanai M; Matsumoto S; Nishimura T; Yazumi S; Kami K; Kawaguchi Y; Yasuda H; Kitano T; Misawa A; Ishiguro H; Yoshikawa K; Yanagihara K; Fukushima M; Doi R; Chiba T Pancreas; 2008 Apr; 36(3):327-8. PubMed ID: 18362852 [No Abstract] [Full Text] [Related]
18. [Outcomes of treatment with gemcitabine for unresectable pancreatic cancer]. Nobutani K; Kutsumi H; Funatsu E; Nishida K; Ikezawa S; Shiomi H; Fukiya E; Suzuki T; Masuda K; Hata K; Nakamura H; Okuyama Y; Kimura H; Yagi N; Sugeta N; Yashiro H; Otsuka H; Suyama Y; Fujimoto S Gan To Kagaku Ryoho; 2004 Feb; 31(2):199-203. PubMed ID: 14997751 [TBL] [Abstract][Full Text] [Related]
19. [Is the frequency of hemolytic uremic syndrome as a complication of gemcitabine underestimated? The role of systematic screening]. Desramé J; Duvic C; Béchade D; Bredin C; Raynaud JJ; Defuentes G; Dourthe LM; Algayres JP Gastroenterol Clin Biol; 2006 Feb; 30(2):332-4. PubMed ID: 16565677 [No Abstract] [Full Text] [Related]
20. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. Ko AH; Dito E; Schillinger B; Venook AP; Bergsland EK; Tempero MA J Clin Oncol; 2006 Jan; 24(3):379-85. PubMed ID: 16344320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]